文献速递乳腺神经腹部MR

治疗前超顺磁性氧化铁增强MRI预测转移性乳腺癌对脂质体伊立替康的应答

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
PubMed 文献 · Radiol Imaging Cancer · 2023-01-01

本1期扩展试验纳入27例转移性乳腺癌患者,分析49处胸腹部和19处脑转移灶在FMX增强MRI上的参数,发现治疗前16-24小时rR*2,90预测胸腹部转移灶应答准确率74%,FCIGT1 R*2,90交叉验证预测脑转移灶应答准确率79%。

要点

  • 治疗前FMX增强MRI的rR*2,90可预测胸腹部转移灶对nal-IRI的应答,准确率74%。
  • FCIGT1 R*2,90交叉验证预测脑转移灶应答的准确率为79%。
  • rR*2,90的预测性能对肿瘤ROI内包含部分瘤周组织是稳健的。

核心结论

  • 这项首次人体研究聚焦mBC,提示FMX增强MRI生物标志物可能有助于治疗前预测mBC患者对nal-IRI的应答。

研究设计与样本

  • 1期扩展试验(ClinicalTrials.gov NCT01770353),纳入27例受试者,分析49处胸腹部转移灶(19例,平均年龄48岁±11)和19处脑转移灶(7例,平均年龄54岁±8),在FMX给药前、给药后1-4小时和16-24小时采集MRI。

关键影像表现/征象

  • 胸腹部转移灶计算肿瘤横向弛豫率R*2归一化至脾脏平均R*2的rR*2,并计算肿瘤直方图指标rR*2,N(第n百分位以上体素rR*2的平均值)。
  • 脑转移灶通过将MRI信号方程应用于体模校准的配准FMX增强MRI脑扫描,推导新的分隔指数。
  • 计算全肿瘤FMX分隔指数大于1的体素分数(FCIGT1)及R*2第90百分位以上体素的FCIGT1(FCIGT1 R*2,90)。

诊断标准与关键数值

  • 治疗前16-24小时FMX增强MRI计算的rR*2,90(无需参考校准体模)预测胸腹部转移灶对nal-IRI的应答,准确率74%。
  • FCIGT1 R*2,90交叉验证预测脑转移灶应答的准确率为79%。

临床应用与阅片要点

  • 治疗前FMX增强MRI的rR*2,90和FCIGT1 R*2,90可能有助于预测mBC患者对nal-IRI的应答。
  • rR*2,90的预测性能对肿瘤ROI内包含部分瘤周组织是稳健的。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To investigate ferumoxytol (FMX)-enhanced MRI as a pretreatment predictor of response to liposomal irinotecan (nal-IRI) for thoracoabdominal and brain metastases in women with metastatic breast cancer (mBC). Materials and Methods In this phase 1 expansion trial (ClinicalTrials.gov identifier, NCT01770353; 27 participants), 49 thoracoabdominal (19 participants; mean age, 48 years ± 11 [SD]) and 19 brain (seven participants; mean age, 54 years ± 8) metastases were analyzed on MR images acquired before, 1-4 hours after, and 16-24 hours after FMX administration. In thoracoabdominal metastases, tumor transverse relaxation rate (R*2) was normalized to the mean R*2 in the spleen (rR*2), and the tumor histogram metric rR*2,N, representing the average of rR*2 in voxels above the nth percentile, was computed. In brain metastases, a novel compartmentation index was derived by applying the MRI signal equation to phantom-calibrated coregistered FMX-enhanced MRI brain scans acquired before, 1-4 hours after, and 16-24 hours after FMX administration. The fraction of voxels with an FMX compartmentation index greater than 1 was computed over the whole tumor (FCIGT1) and from voxels above the 90th percentile R*2 (FCIGT1 R*2,90). Results rR*2,90 computed from pretherapy MRI performed 16-24 hours after FMX administration, without reference to calibration phantoms, predicted response to nal-IRI in thoracoabdominal metastases (accuracy, 74%). rR*2,90 performance was robust to the inclusion of some peritumoral tissue within the tumor region of interest. FCIGT1 R*2,90 provided 79% accuracy on cross-validation in prediction of response in brain metastases. Conclusion This first in-human study focused on mBC suggests that FMX-enhanced MRI biologic markers can be useful for pretherapy prediction of response to nal-IRI in patients with mBC. Keywords: MRI Contrast Agent, MRI, Breast, Head/Neck, Tumor Response, Experimental Investigations, Brain/Brain Stem Clinical trial registration no. NCT01770353 Supplemental material is available for this article. © RSNA, 2023 See also commentary by Daldrup-Link in this issue.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Ravi H, Arias-Lorza AM, Costello JR, et al. Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. Radiol Imaging Cancer. 2023. PMID: 36734848. doi:10.1148/rycan.220022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。